Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Plasma Protein Biomarkers for Early Detection of Pancreatic Cancer.

Created on 15 Jul 2026

Authors

Yingsong Lin, Masahiro Nakatochi, Haruki Sasado, Itsuki Kageyama, Sayo Kawai, Taiki Yamaji, Naoki Sasahira, Masato Ozaka, Hiroshi Ishii, Makoto Ueno, Satoshi Kobayashi, Naoto Egawa, Yasushi Adachi, Yuki Obata, Yuki Ohashi, Tae Sasakabe, Asahi Hishida, Shogo Kikuchi

Published in

International journal of cancer. Jul 14, 2026. Epub Jul 14, 2026.

Abstract

Early detection of pancreatic cancer remains challenging, and reliable circulating biomarkers are needed to enable earlier diagnosis and improve clinical outcomes. We conducted a plasma proteomics study using the Olink Explore HT platform to identify novel biomarker candidates for early-stage pancreatic cancer. The study included 42 patients with stage I-II pancreatic cancer and 43 matched controls. Plasma protein levels were quantified using the Olink Proximity Extension Assay, and differential abundance was assessed using Welch's t-test with correction for multiple testing. Diagnostic performance was evaluated using the area under the receiver operating characteristic curve (AUC). Among 5419 proteins analyzed, 982 showed significant differences between cases and controls. Carboxylesterase 3 (CES3) was the most significantly decreased protein, whereas leukocyte immunoglobulin-like receptor B4 (LILRB4) was the most significantly increased protein; both demonstrated excellent diagnostic performance (AUC = 0.91). In addition, pancreatic polypeptide (PPY) showed markedly reduced levels in patients with tumors arising in the head of the pancreas, suggesting anatomical specificity. This comprehensive Olink-based proteomic analysis identifies CES3 and LILRB4 as promising plasma biomarkers for early-stage pancreatic cancer and highlights PPY as informative for tumor localization. These findings provide a valuable resource for biomarker discovery and support further validation of these candidates for noninvasive early detection and risk stratification.

PMID:
42447929
Bibliographic data and abstract were imported from PubMed on 15 Jul 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 6
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement